Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Issues Quarterly Earnings Results

by · The Cerbat Gem

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23), FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock traded down $1.27 during midday trading on Tuesday, hitting $23.09. 520,843 shares of the company were exchanged, compared to its average volume of 254,854. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33. The firm has a market capitalization of $1.39 billion, a P/E ratio of -1.91 and a beta of 1.50. The firm’s 50 day moving average price is $26.02 and its two-hundred day moving average price is $23.72.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently made changes to their positions in the company. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $6,574,000. Janus Henderson Group PLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $40,000. Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,204,000. Jain Global LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,774,000. Finally, Remedium Capital Partners LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $2,772,000. Institutional investors own 14.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DMRA shares. UBS Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “buy” rating and a $45.00 price objective on the stock. Guggenheim reiterated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Finally, Evercore initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.40.

Check Out Our Latest Analysis on DMRA

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

Further Reading